Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model

By Kreck Simon   Klaus Jochen  

PharmacoEconomics, Vol. 26, Iss. 4, 2008-01 ,pp. : 311-328

Adis International

Access to resources Recommend Favorite

A Markov Model of the Cost Effectiveness of Olanzapine Treatment for Agitation and Psychosis in Alzheimer's Disease

By Kirbach Stephanie  

Clinical Drug Investigation, Vol. 28, Iss. 5, 2008-01 ,pp. : 291-303

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of pharmacotherapy for autoimmune hepatitis

By Heneghan Michael A   Al-Chalabi Thawab   McFarlane Ian G  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 2, 2006-02 ,pp. : 145-156

Informa Healthcare

Access to resources Recommend Favorite

The Cost Effectiveness and Cost Utility of Valsartan in Chronic Heart Failure Therapy in Italy: A Probabilistic Markov Model

By Pradelli Lorenzo   Iannazzo Sergio   Zaniolo Orietta  

American Journal of Cardiovascular Drugs, Vol. 9, Iss. 6, 2009-12 ,pp. : 383-392

Adis International

Access to resources Recommend Favorite

Choice of Cost-Effectiveness Measure in the Economic Evaluation of Cholesterol-Modifying Pharmacotherapy: An Illustrative Example Focusing on the Primary Prevention of Coronary Heart Disease in Canada

By Morris S.  

PharmacoEconomics, Vol. 16, Iss. 2, 1999-08 ,pp. : 193-205

Adis International

Access to resources Recommend Favorite